SCHEMBL19965191

SCHEMBL19965191

CC(C)(C)OC(=O)NCCCCCCN1CCCC[C@H](NC(=O)OC(C)(C)C)C1=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46
PRSS1 P07477 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
EPHX1 P07099 1/20 0.44
DRD2 P14416 7/20 0.43
MMP1 P03956 3/20 0.42
MMP3 P08254 3/20 0.42
MAN2B1 O00754 1/20 0.40
TPSAB1 Q15661 1/20 0.40
TPSD1 Q9BZJ3 1/20 0.40
TPSG1 Q9NRR2 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CHRM2 P08172 2/20 0.39
CHRM4 P08173 2/20 0.39
CHRM5 P08912 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM3 P20309 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19965194 0.96 F2 (0.48) F2F10PRSS1TDP1EPHX1
SCHEMBL28938876 0.96 F2 (0.48) F2F10PRSS1TDP1EPHX1
SCHEMBL21066904 0.94 TDP1 (0.42) F2F10PRSS1TDP1EPHX1
SCHEMBL21066903 0.94 TDP1 (0.42) F2F10PRSS1TDP1EPHX1
SCHEMBL23005330 0.89 EPHX1 (0.44) F2F10PRSS1TDP1EPHX1
SCHEMBL23005331 0.89 EPHX1 (0.44) F2F10PRSS1TDP1EPHX1
SCHEMBL7471624 0.86 MMP1 (0.49) F2F10PRSS1MMP1MMP3
SCHEMBL13818430 0.85 F2 (0.45) F2F10PRSS1MMP1MMP3
SCHEMBL13818432 0.85 F2 (0.45) F2F10PRSS1MMP1MMP3
SCHEMBL15130754 0.84 F2 (0.51) F2F10PRSS1MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4595969-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE Temple University Of The Commonwealth System Of Higher Education (US) 2025-08-06 EP disclosed
EP-3509575-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE UNIV TEMPLE (US) 2025-03-19 EP disclosed
US-11596615-B2 Compositions and methods for treatment of insulin resistance Temple University—Of the Commonwealth System of Higher Education (US) 2023-03-07 US disclosed
US-20210052532-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-02-25 US disclosed
US-20210052532-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-02-25 US disclosed
US-20210046030-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-02-18 US disclosed
US-10729670-B2 Compositions and methods for treatment of insulin resistance Temple University—Of The Commonwealth Systems Of Higher Education (US) 2020-08-04 US disclosed
US-20190192462-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2019-06-27 US disclosed
WO-2018049019-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052532-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE GPR119, FABP4, SLC2A3 F2 3484/4885F10 4541/4885PRSS1 4056/4885
US-11596615-B2 Compositions and methods for treatment of insulin resistance GPR119, INSR, IAPP F2 1479/4885F10 1295/4885PRSS1 2035/4885
US-10729670-B2 Compositions and methods for treatment of insulin resistance GPR119, INSR, IAPP F2 1479/4885F10 1295/4885PRSS1 2035/4885
US-20190192462-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE GPR119, INSR, IAPP F2 1479/4885F10 1295/4885PRSS1 2035/4885
US-20210046030-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE GPR119, INSR, IAPP F2 1479/4885F10 1295/4885PRSS1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.